The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwMyeloma 2017 | Liquid biopsies for multiple myeloma: the attractions and limits
Technological advances have allowed for whole genome, exome and transcriptome sequencing of circulating multiple myeloma (MM) cells and cell-free tumor DNA. In this video, Jens Lohr, MD, PhD from the Dana-Farber Cancer Institute, Boston, MA, highlights the advantages of this. Dr Lohr also addresses the limitation of liquid biopsies, including patient selection and standardization. This video was recorded at the Myeloma 2017 meeting in Edinburgh, UK.
